Skip to main content
Premium Trial:

Request an Annual Quote

Newsham Genetics To Acquire Monsanto Genomics Unit

NEW YORK (GenomeWeb News) - Newsham Genetics said yesterday that it has signed a definitive agreement to purchase Monsanto Choice Genetics, a subsidiary of the agricultural giant.
The transaction will be completed “as soon as practical,” Newsham said.
In a statement, Newsham said it “placed high value on the significant investment made by MCG over the past 10 years in their genomics platform.”
Newsham’s Co-CEO Mike Weaver noted that MCG has developed “the most extensive swine genomic map in the industry, with over 6,000 genomic marker associations for swine performance,” which is expected to help Newsham to “accelerate genetic progress across many different traits for the industry."
According to Newsham’s Co-CEO Brent Mitchell, MCG and Newsham are currently the second and third largest swine genetics companies, respectively. The acquisition, he said, “will create a very strong and vibrant player in the North American market with the most extensive technology in the industry.”
As part of the agreement, the companies have entered a three-year research alliance that will focus on the MCG genomics platform “to maximize the value created in the industry from these tools.”

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.